Advertisement

X (Twitter) LinkedIn Facebook

X (Twitter) LinkedIn Facebook

Cancer Specialty
Conference Coverage
- AACR 2024
- ASCO GI 2024
- ASH 2023
- ASCO 2023
- SABCS 2023
- MOASC

Advertisement

Browsing: relapsed refractory

Advertisement

Recent Posts

FDA D.I.S.C.O. Burst Edition: FDA approval of Polivy (polatuzumab vedotin-piiq) for previously untreated diffuse large B-cell lymphoma, not otherwise specified, and high-grade B-cell lymphoma
FDA D.I.S.C.O. Burst Edition: FDA approval of Ayvakit (avapritinib) for adult patients with advanced systemic mastocytosis, including patients with aggressive systemic mastocytosis, systemic mastocytosis with an associated hematological neoplasm, and mast cell leukemia
KRYSTAL-1: Adagrasib + Cetuximab Promise for KRASG12C Colorectal Cancer – Scott Kopetz, MD [AACR 2024]
Revolutionizing Pancreatic Cancer Detection: The Groundbreaking Role of Liquid Biopsies – Ajay Goel, PhD [AACR 2024]
Targeting SCD1 in KRAS Mutant Non-Small Cell Lung Cancer: A Novel Therapeutic Strategy

X (Twitter) LinkedIn Facebook

© 2024 Copyright Protected Medicus Networks, Inc..

Type above and press Enter to search. Press Esc to cancel.